| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 14.3 | 14.2 | 12.5 |
| Other income | 0.1 | 0.0 | 0.1 |
| Total income | 14.3 | 14.2 | 12.6 |
| Profit before exceptional items & tax | 0.3 | 0.9 | 1.5 |
| Profit before tax | 0.3 | 0.3 | 1.5 |
| Net profit | 0.2 | -5.2 | 1.3 |
| Operating margin | 2.1% | 2.1% | 11.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -84.60% |
|---|---|
| Revenue, year on year | +14.40% |
BSE results filing, NSE: VIVOBIOT. Figures extracted from the filing.
Vivo Bio Tech Ltd: key numbers
- Share price
- ₹14.00
- Market cap
- ₹22.58 Cr
- Revenue (annual)
- ₹53.33 Cr
- Net profit (annual)
- ₹-1.71 Cr
- P/E (TTM)
- -7.9×Sector 47.4×
- Promoter holding
- 30.62%-4.81% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivo Bio Tech Ltd
All →Vivo Bio Tech Other Announcement
Vivo Bio Tech has sent letters to shareholders without registered email addresses, providing a web-link to access the Annual Report for the financial year 2025-26.
Vivo Bio Tech Annual Report
Vivo Bio Tech Limited has submitted its Annual Report for the financial year 2025-2026 along with the notice for its 39th Annual General Meeting.
Vivo Bio Tech Annual General Meeting
Vivo Bio Tech Ltd issued a notice for its 39th Annual General Meeting to be held on September 30, 2026, via video conferencing.
Vivo Bio Tech Promoter Selling (Off-Market)
P.K.L Solution Private Limited, a promoter group entity, sold 6,00,000 equity shares of Vivo Bio Tech Limited. This off-market transaction reduced their stake to nil.
Vivo Bio Tech Management Change
Vivo Bio Tech Limited announced the re-appointment of Mr. Sri Kalyan Kompella and Mr. Sankaranarayanan Alangudi as Executive Directors of the company.
Vivo Bio Tech Board Meeting Outcome
Vivo Bio Tech's board meeting approved the 39th AGM date and the re-appointment of three Whole-Time Directors.